共 157 条
[1]
Pepin J.(1995)Risk-factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma-Brucel-Gambiense sleeping sickness Trans. of the Roy. Soc. of Trop. Med. and Hyg. 89 92-97
[2]
Milord F.(1996)Topical chemotherapy for experimental murine African CNS-trypanosomiasis: The successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436 Trop. Med. & Internat. Health. 1 590-598
[3]
Khonde N.(1996)Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: The use of melarsoprol combined with the 5-nitroimidazole, megazol Trop. Med. & Internat. Health 1 363-366
[4]
Niyonsenga T.(1992)Human studies with the chelating agents, DMPS and DMSA Clin. Toxicol. 30 505-28
[5]
Loko L.(1972)The pharmacology of mercury compounds Annu. Rev. Pharmacol. Toxicol. 12 375-406
[6]
Mpia B.(1990)Mercury-An element of mystery N. Engl. J. Med. 323 1137-39
[7]
Dewals P.(1994)Mercury kinetics in a case of severe mercuric chloride poisoning treated with dimercapto-1-propane sulphonate (DMPS) Hum. & Exper. Toxicol. 13 11-16
[8]
Jennings F. W.(1996)Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rats Toxicology 109 49-55
[9]
Atouguia J. M.(1995)Treatment of mercury and lead poisonings with dimercaptosuccinic acid and sodium dimercaptopropanesulfonate Analyst 120 853-854
[10]
Murray M.(1998)Aminolevulinate dehydratase inhibition by 2,3-dimercaptopropanol is mediated by chelation of zinc from a site involved in maintaining cysteinyl residues in a reduced state Pharmacol. & Toxicol. 83 95-103